规格 | 价格 | 库存 | 数量 |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
靶点 |
5-HT2A Receptor ( Ki = 4 nM ); 5-HT1 Receptor ( Ki = 7 nM ); 5-HT6 Receptor ( Ki = 5 nM ); 5-HT2C Receptor ( Ki = 11 nM ); 5-HT3 Receptor ( Ki = 57 nM ); Adrenergic α1 Receptor ( Ki = 19 nM ); Muscarinic M1-5 Receptor ( Ki = 1.9-25 nM ); Dopamine Receptor; Mitophagy; Apoptosis
|
||
---|---|---|---|
体外研究 (In Vitro) |
体外活性:奥氮平与精神分裂症中感兴趣的关键受体相互作用,对多巴胺能、血清素能、α1-肾上腺素能和毒蕈碱受体具有纳摩尔亲和力。奥氮平的受体谱与氯氮平相似:它对多巴胺受体亚型相对无选择性,并且对中脑边缘和中皮质层比纹状体多巴胺束具有选择性(电生理学;Fos)。
|
||
体内研究 (In Vivo) |
奥氮平是 DA 受体(DOPAC 水平;培高利特刺激的血浆皮质酮增加)和 5-HT 受体(奎帕嗪刺激的皮质酮增加)的有效拮抗剂,但对 α-肾上腺素能和毒蕈碱受体的作用较弱。奥氮平与氟西汀联合使用可使大鼠前额皮质细胞外多巴胺 ([DA](ex)) 和去甲肾上腺素 ([NE](ex)) 水平强劲、持续增加,分别高达基线的 361% 和 272%,显着大于单独使用任何一种药物。 0.5 mg/kg、3 mg/kg 和 10 mg/kg (sc) 的奥氮平剂量依赖性地增加大鼠前额皮质、伏隔核和纹状体中的细胞外多巴胺 (DA) 和去甲肾上腺素 (NE) 水平。奥氮平还可增加 DA 代谢物 DOPAC 的细胞外水平以及释放的 DA 代谢物 3-甲氧基酪胺的组织浓度。奥氮平可使猕猴的平均新鲜脑重量以及左脑新鲜重量和体积减少 8-11%。奥氮平导致肥胖显着增加:全身脂肪增加反映了皮下和内脏脂肪储存的显着增加。奥氮平会导致明显的肝脏胰岛素抵抗。
|
||
动物实验 |
|
||
参考文献 |
分子式 |
C17H20N4S
|
|
---|---|---|
分子量 |
312.44
|
|
精确质量 |
312.14
|
|
元素分析 |
C, 65.35; H, 6.45; N, 17.93; S, 10.26
|
|
CAS号 |
132539-06-1
|
|
相关CAS号 |
Olanzapine-d3; 786686-79-1
|
|
外观&性状 |
Solid powder
|
|
SMILES |
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
|
|
InChi Key |
KVWDHTXUZHCGIO-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
|
|
化学名 |
2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
|
|
别名 |
|
|
HS Tariff Code |
2934.99.9001
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 3.2006 mL | 16.0031 mL | 32.0061 mL | |
5 mM | 0.6401 mL | 3.2006 mL | 6.4012 mL | |
10 mM | 0.3201 mL | 1.6003 mL | 3.2006 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02088060 | Active Recruiting |
Drug: Cannabidiol Drug: Olanzapine |
Schizophrenia | Central Institute of Mental Health, Mannheim |
December 8, 2015 | Phase 2 |
NCT05213143 | Active Recruiting |
Drug: Lurasidone | Schizophrenia | Sumitomo Pharma (Suzhou) Co., Ltd. |
December 30, 2021 | Phase 4 |
NCT00512070 | Active Recruiting |
Drug: olanzapine and melatonin |
Schizophrenia Obesity |
Seattle Institute for Biomedical and Clinical Research |
July 2007 | Not Applicable |
NCT05244577 | Recruiting | Drug: Olanzapine Tablets Drug: Placebo |
Olanzapine CINV Cisplatin |
Shi Yanxia | January 18, 2022 | Phase 3 |
NCT05243251 | Recruiting | Drug: Olanzapine 5 MG Drug: Placebo |
Anorexia | Cairo University | December 25, 2021 | Phase 3 |
Effects of olanzapine (3 mg/kg, s.c.) and fluoxetine (10 mg/kg, s.c.) alone and in combination on [5-HT]ex (A), [DA]ex (B), and [NE]ex (C) in the rat prefrontal cortex. Neuropsychopharmacology . 2000 Sep;23(3):250-62. td> |
Effects of olanzapine (3 mg/kg, s.c.) and sertraline (10 mg/kg, s.c.) alone and in combination on [5-HT]ex (A), [DA]ex (B), and [NE]ex (C) in the rat prefrontal cortex. Neuropsychopharmacology . 2000 Sep;23(3):250-62. td> |
Administrated daily drug dose as a function of time for each monkey in the haloperidol- (left) and olanzapine- (right) exposed groups. Neuropsychopharmacology . 2005 Sep;30(9):1649-61. td> |
Increase in mean body weights for each group (S, sham; H, haloperidol; O, olanzapine) across the course of the study. Neuropsychopharmacology . 2005 Sep;30(9):1649-61. td> |
Fresh brain weights for the sham- (S), haloperidol- (H) and olanzapine- (O) exposed monkeys. Neuropsychopharmacology . 2005 Sep;30(9):1649-61. td> |